People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mainz Biomed N.V. | — | Biotechnology | Series A | $14.9M | $122.3M | 2023 |
Gregory Tibbits at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gregory Tibbits on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Heiner Dreismann | 1 | 6 |
| William Caragol | 1 | 2 |
| Guido Baechler | 1 | 1 |
| Alberto Libanori | 1 | 1 |
| Moritz Eidens | 1 | 1 |
| Nicole Holden | 1 | 1 |
| Hans Hekland | 1 | 1 |
| Darin Leigh | 1 | 1 |
| Marco Messina | 1 | 1 |
| Phillip Freese | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.